Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced tha...
Is there any anticipated change in the managementās guidance or communication strategy following the COLLECTiVE202 results?
What additional data (e.g., safety, biomarker, subgroup analyses) were disclosed that could affect future strategic decisions?
How might this outcome influence the likelihood of a future shareārepurchase program or secondary offering?
11 days ago